drugset / Trial / NCT05363215

A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants

NCT05363215

Phase 1 Completed 32 enrolled Shionogi
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to measure the PK, safety, and tolerability of S-217622 in participants with mild, moderate, or severe renal impairment and in those with normal renal function.

Timeline

Start
2022-08-10
Primary completion
2023-04-12
Completion
2023-04-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ensitrelvir Small molecule Oral